Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Emotional expression

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44365   clinical trials with a EudraCT protocol, of which   7389   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    15 result(s) found for: Emotional expression. Displaying page 1 of 1.
    EudraCT Number: 2017-004823-66 Sponsor Protocol Number: ELTCAN1 Start Date*: 2019-04-17
    Sponsor Name:Radboudumc
    Full Title: Early-life stress, the endocannabinoid system, and fear memory extinction
    Medical condition: healthy volunteers
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10036876 Prolonged posttraumatic stress disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-003728-39 Sponsor Protocol Number: OTMother2014 Start Date*: 2014-12-16
    Sponsor Name:Tampere University Hospital
    Full Title: Effects of maternal oxytocin on social information processing in mothers
    Medical condition: There are no medical conditions or diseases under investigation, participants are healthy volunteers.
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004606-60 Sponsor Protocol Number: BP42772 Start Date*: 2021-06-22
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A 3-ARM, RANDOMIZED, BLINDED, ACTIVE-CONTROLLED, PHASE II STUDY OF RO7121661, A PD1-TIM3 BISPECIFIC ANTIBODY AND RO7247669, A PD1-LAG3 BISPECIFIC ANTIBODY, COMPARED WITH NIVOLUMAB IN PARTICIPANTS W...
    Medical condition: Advanced or metastatic squamous cell carcinoma of the esophagus
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10015362 Esophageal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Trial now transitioned) DK (Trial now transitioned) HU (Trial now transitioned) BE (Completed) FR (Trial now transitioned) IT (Trial now transitioned) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-006773-38 Sponsor Protocol Number: TSPOC5FOR2022 Start Date*: 2022-11-29
    Sponsor Name:Medizinische Einrichtungen des Berzirks Oberpfalz
    Full Title: TSPO ligands in the treatment of depression: proof-of-concept of efficacy and underlying mechanisms of action
    Medical condition: Unipolar/bipolar depressive disorder
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-000418-75 Sponsor Protocol Number: TV5600-CNS-20007 Start Date*: 2014-11-18
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: A Multicenter, Multinational, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/day) as Treatment in Patients...
    Medical condition: Huntington's Disease (HD)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10010331 - Congenital, familial and genetic disorders 10070668 Huntington's disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed) GB (Completed) CZ (Completed) DE (Completed) PT (Completed) NL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-004212-48 Sponsor Protocol Number: CRH108571 Start Date*: 2007-01-24
    Sponsor Name:GlaxoSmithKline S.A.
    Full Title: Estudio doble ciego, aleatorizado, controlado con placebo y alprazolam, de diseño cruzado con tres periodos y bloques incompletos, para comparar mediante Resonancia Magnética Funcional, las posibl...
    Medical condition: Fobia Social (SAD)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-000453-35 Sponsor Protocol Number: EPO-AD-01-2008 Start Date*: 2008-06-30
    Sponsor Name:Max-Planck-Institute of Experimental Medicine
    Full Title: Open-label phase IIa pilot study exploring safety and potential efficacy of recombinant human erythropoietin in early mild Alzheimer Dementia and therapy-refractory Major Depression (“EPO-AD”)
    Medical condition: Early, mild dementia of the Alzheimer’s Type and therapy-refractory Major Depression
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012271 Dementia Alzheimer's type LLT
    9.1 10066555 Chronic depression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-002344-23 Sponsor Protocol Number: 2020/490 Start Date*: 2020-08-19
    Sponsor Name:CHU de Besançon
    Full Title: Regorafenib in combination with metronomic cyclophosphamide, capecitabine, and low-dose aspirin in metastatic colorectal cancer carcinoma An open-label phase II
    Medical condition: Metastatic colorectal cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002889-41 Sponsor Protocol Number: UC-BCG-2103 Start Date*: 2022-04-29
    Sponsor Name:UNICANCER
    Full Title: LESS: Single-arm study to de-escalate adjuvant endocrine therapy duration in women with HR+ HER2- breast cancer at very low risk of metastasis
    Medical condition: Post-menopausal women with localized luminal A breast cancer and considered at low risk of metastatic relapse
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10083237 Luminal A breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-000999-11 Sponsor Protocol Number: MNPR-301-001 Start Date*: 2021-09-23
    Sponsor Name:Monopar Therapeutics Inc.
    Full Title: A Phase 2b/3, multicenter, randomized, double-blind, placebocontrolled study comparing the efficacy and safety of clonidine mucoadhesive buccal tablet to placebo to prevent chemoradiotherapy-induce...
    Medical condition: Chemoradiotherapy (CRT)-induced severe oral mucositis (SOM) in patients with oropharyngeal cancer (OPC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10028130 Mucositis oral LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-000140-58 Sponsor Protocol Number: NL7255100000 Start Date*: 2020-07-23
    Sponsor Name:Leiden University Medical Center
    Full Title: Complement Inhibition: Attacking the Overshooting Inflammation @fter Traumatic Brain Injury - A phase II trial on the safety and efficacy of C1 esterase inhibitor Cinryze for the acute management o...
    Medical condition: Severe traumatic Brain Injury (TBI) with GCS < 13
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004863 10060690 Traumatic brain injury LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-000215-32 Sponsor Protocol Number: Pycno2015-14 Start Date*: 2016-10-04
    Sponsor Name:University of Antwerp
    Full Title: Effect of Pycnogenol® on Attention-Deficit Hyperactivity Disorder (ADHD): A randomized, double blind, placebo and active product controlled multicenter trial.
    Medical condition: Attention-deficit hyperactivity disorder (ADHD)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10037175 - Psychiatric disorders 10003737 Attention deficit/hyperactivity disorder NOS LLT
    19.0 10037175 - Psychiatric disorders 10003736 Attention deficit/hyperactivity disorder PT
    19.0 10037175 - Psychiatric disorders 10003735 Attention deficit-hyperactivity disorder LLT
    19.0 10037175 - Psychiatric disorders 10003734 Attention deficit disorder of childhood without mention of hyperactivity LLT
    19.0 10037175 - Psychiatric disorders 10003733 Attention deficit disorder of childhood with hyperactivity LLT
    19.0 10037175 - Psychiatric disorders 10003732 Attention deficit disorder of childhood LLT
    19.0 10037175 - Psychiatric disorders 10003731 Attention deficit disorder LLT
    19.0 100000004852 10003729 Attention concentration difficulty LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-006067-28 Sponsor Protocol Number: CST103/CST107-CLIN-011 Start Date*: 2022-01-10
    Sponsor Name:CuraSen Therapeutics, Inc.
    Full Title: A Phase II, Randomized, Placebo-Controlled, Double-Blind, Crossover, Study of the Pharmacodynamic Effects of CST-103 co-administered with CST-107 on the Central Nervous System in Subjects with Neur...
    Medical condition: Patients with Parkinson’s Disease with REM sleep behaviour disorder, Mild Cognitive Impairment, Dementia with Lewy Bodies and Parkinson’s Disease Dementia.
    Disease: Version SOC Term Classification Code Term Level
    24.0 10029205 - Nervous system disorders 10012284 Dementia due to Parkinson's disease LLT
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    21.1 10029205 - Nervous system disorders 10009846 Cognitive impairment LLT
    20.0 10029205 - Nervous system disorders 10067889 Dementia with Lewy bodies PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2018-000366-11 Sponsor Protocol Number: ENGOT-Ov41/GEICO69-O/ANITA Start Date*: 2018-10-31
    Sponsor Name:Grupo Español de Investigación en Cáncer de Ovario (GEICO)
    Full Title: A phase III randomized, double-blinded trial of platinum-based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ov...
    Medical condition: Recurrent ovarian, tubal or peritoneal cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10033130 Ovarian cancer NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Restarted) FR (Completed) DE (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-003392-32 Sponsor Protocol Number: 2014/VCC/0014 Start Date*: 2014-10-24
    Sponsor Name:Velindre NHS Trust
    Full Title: A Phase II/III trial of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for Human papillomavirus (HPV)-positive oropharyngeal cancer
    Medical condition: Oropharyngeal cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10031096 Oropharyngeal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) DE (Trial now transitioned) ES (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Dec 07 13:58:06 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA